Study Overview
This study explored the effects of a 6-week treatment with two types of probiotics on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Background
IBS-D patients often experience increased intestinal permeability. Probiotics may help improve IBS symptoms and support gut health.
Aim
The study aimed to see how Limosilactobacillus reuteri ATCC PTA 6475 (single strain) and Limosilactobacillus reuteri DSM 17938 (dual strain) affect gut barrier function, immune markers, and IBS symptoms.
Methods
65 IBS-D patients were divided into three groups: placebo, single strain, and dual strain. Researchers measured gut permeability and collected various samples before and after the treatment.
Results
- Probiotic treatments did not significantly change gut barrier function.
- There was a slight reduction in inflammation markers in the single strain group.
- The dual strain group showed a significant decrease in high-sensitivity C-reactive protein.
- Both treatment groups reported fewer gastrointestinal symptoms after three weeks, with significant improvement in the dual strain group.
- After six weeks, no significant differences in symptoms were observed compared to the placebo group.
Conclusion
The probiotics studied did not significantly improve gut barrier function in IBS-D patients but showed potential for reducing inflammation and improving symptoms. Further research with larger groups is needed.
Practical Solutions and Value
Clinical trials are essential for developing effective treatments. Our AI-driven platform, DocSym, integrates clinical standards and research, making it easier for healthcare providers to access vital information.
In today’s healthcare landscape, efficiency is key. Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, enhancing patient care and expanding digital services.
By leveraging AI, clinics can streamline operations, improve patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
